Deleted in Liver Cancer 1 (DLC1) is a tumor suppressor whose allele is lost in 50% of liver, breast, lung and 70% of colon cancers. Here, we show that the transcriptional coactivators Megakaryoblastic Leukemia 1 and 2 (MKL1/2) are constitutively localized to the nucleus in hepatocellular and mammary carcinoma cells that lack DLC1. Moreover, DLC1 loss and MKL1 nuclear localization correlate in primary human hepatocellular carcinoma. Nuclear accumulation of MKL1 in DLC1-deficient cancer cells is accomplished by activation of the RhoA/actin signaling pathway and concomitant impairment of MKL1 phosphorylation, which results in constitutive activation of MKL1/2 target genes. We provide evidence that MKL1/2 mediates cancerous transformation in DLC1-deficient hepatocellular and mammary carcinoma cells. Depletion of MKL1/2 suppresses cell migration, cell proliferation and anchorage-independent cell growth induced by DLC1 loss.
Introduction
Megakaryoblastic Leukemia 1 and 2 proteins (MKL1/2) are coactivators of the transcription factor serum response factor (SRF). SRF controls many fundamental biological processes such as cell growth, cell migration, differentiation and organization of the cytoskeleton via approximately 160 different target genes (Pipes et al., 2006) . The association of SRF with the coactivator MKL1 (MRTF-A, MAL, BSAC) and MKL2 (MRTF-B) links gene transcription to changes in actin dynamics. In response to RhoA-induced actin polymerization and concomitant G-actin depletion, MKL1/2 accumulates in the nucleus and activates gene transcription through SRF (Miralles et al., 2003) . Nuclear export of MKL1 is facilitated by binding of G-actin to the Nterminus of MKL1 (Vartiainen et al., 2007) . Work from our laboratory revealed that phosphorylation of MKL1 by ERK1/2 enhances G-actin binding and nuclear export of MKL1 (Muehlich et al., 2008) . Although the regulation of MKL1 nuclear entry and export is well established in fibroblasts, the pathophysiologic relevance, however, remains to be investigated.
Both the RhoA and ERK 1/2 MAP kinase pathways that regulate MKL1 nuclear export have been implicated in cancer. Activation of ERK1/2 MAP kinase signaling by the oncogenes Ras and Raf and their role in tumor progression are well characterized (Wilhelm et al., 2004; Giehl, 2005; Gollob et al., 2006) . RhoA overexpression has been found in various cancers (Gomez del Pulgar et al., 2005) , but the mechanisms for RhoA activation, the downstream mediators and transcription factors involved remain largely elusive. The closely related RhoC gene has particularly been shown to have a role in metastasis. High RhoC expression was found to be required for the metastatic potential of melanoma cells in mice and loss of RhoC reduced metastases in Polyoma middle T transgenic mice (Clark et al., 2000; Hakem et al., 2005) .
Further evidence to support a role for Rho pathways in cancer has come from the identification of the tumor suppressor Deleted in Liver Cancer 1 (DLC1) whose loss potentiates RhoA activity (Yuan et al., 1998; Xue et al., 2008) . DLC1 is a RhoGAP protein, which increases the intrinsic GTPase activity of Rho GTPases to accelerate their return to the inactive state (Jaffe and Hall, 2005) . The DLC1 gene was originally identified as a candidate tumor suppressor gene in human hepatocellular carcinoma (HCC) (Yuan et al., 1998) . HCC is among the most lethal and common human cancers in the human population (Farazi and DePinho, 2006) . Despite its significance, the molecular mechanisms that drive liver cell transformation upon DLC1 loss remain unclear. A representative oligonucleotide microarray analysis showed heterozygous deletion of DLC1 in B50% of liver, breast, lung and 70% of colon cancers, almost as frequently as p53 mutations in these cancers (Lahoz and Hall, 2008; Xue et al., 2008) .
In this study, we report that DLC1 loss causes nuclear localization of MKL1/2 in hepatocellular and mammary carcinoma cell lines. A correlation between MKL1 nuclear localization and DLC1 loss was also observed in HCC. Nuclear accumulation of MKL1/2 was accompanied by constitutive activation of tumor-relevant MKL/ SRF-dependent target genes. In addition, we demonstrate a requirement of MKL1/2 for cancer cell specific features caused by DLC1 loss, such as anchorage-independent cell growth, cell migration and cell proliferation.
Results
Nuclear localization of MKL1/2 in cancer cell lines with DLC1 loss We first analyzed the localization of MKL1 in several hepatocellular and breast carcinoma cell lines (HuH7, HCC1143, MDA-MB-453, MDA-MB-468, MCF7), as well as in breast epithelial cells (MCF10F) and human hepatoma cells (Hep3B, HepG2). MKL1 exhibited predominantly nuclear localization in HuH7, HCC1143, MDA-MB-453 and MDA-MB-468 cells, whereas cytoplasmic MKL1 localization was observed in Hep3B, HepG2, MCF7 and MCF10F cells (Figure 1a) . MKL2 showed the same subcellular distribution ( Figure 1a ). As MKL1/2 localization is regulated by RhoA, we screened for altered expression of the tumor suppressor DLC1, which has RhoGAP activity. HuH7, HCC1143, MDA-MB-453 and MDA-MB-468 cells express low levels of the tumor suppressor DLC1 protein (Figure 1b ). This distinguishes them from Hep3B, HepG2, MCF10F and MCF7 cells that did express DLC1.
To investigate whether DLC1 loss leads to nuclear localization of MKL1 and MKL2, we used hepatocytes that were depleted of DLC1 with a specific shRNA (Xue et al., 2008) . The knockdown (KD) efficiency of DLC1 is shown in Figure 6a and Supplementary Figure S1 . Compared with control shRNA, DLC1 shRNA resulted in nuclear accumulation of MKL1 and MKL2 (Figure 1c) . We also reintroduced Flag-tagged DLC1 in HuH7 cells. HuH7 cells transfected with empty vector displayed nuclear localization of MKL1 and 2. In contrast, HuH7 cells expressing recombinant DLC1 showed a redistribution of MKL1 and 2 to the cytoplasm ( Figure 1d and Supplementary Figure S2 ). Taken together, these results implicate an effect of DLC1 expression on MKL1/2 subcellular distribution.
Correlation between MKL1 nuclear localization and DLC1 loss in human HCC DLC1 was originally identified as a tumor suppressor frequently deleted in human HCC (Yuan et al., 1998) . Along with the finding that MKL1 resides in the nucleus of HuH7 cells, we analyzed MKL1 expression and subcellular localization in primary human HCC versus normal liver tissue to determine the correlation between DLC1 loss and MKL1 nuclear localization in vivo.
On the basis of immunohistochemical analyses, normal liver samples did not show significant levels of MKL1 expression, whereas MKL1 was detectable in 26% of HCCs (30/118) . In these samples, MKL1 was nuclear in 53% of cases (16/30). We analyzed DLC1 expression by immunohistochemistry in the same tumor samples. Consistent with our results in hepatocellular and mammary carcinoma cells, HCCs positive for nuclear MKL1 exhibited significantly decreased DLC1 expression compared with normal liver tissue (Figures 2a-e) . Nuclear accumulation of MKL1 was also associated with a significantly higher expression of the proliferation marker Ki-67 (Figure 2f ). These data suggest that loss of DLC1 and subsequent MKL1 accumulation in the nucleus are likely to be pro-tumorigenic events in human hepatocarcinogenesis.
Activation of the RhoA/actin signaling pathway upon DLC1 loss leads to nuclear localization of MKL1 On the basis of the nuclear localization of MKL1 in DLC1-deficient cells, we hypothesized that activation of the RhoA/actin signaling pathway upon DLC1 loss may cause MKL1 nuclear accumulation. To test this hypothesis, we assessed the RhoA activation status in DLC1-deficient MDA-MB-468 versus DLC1-expressing MCF7 cells by immunoprecipitation with an antibody that specifically recognizes GTP-bound RhoA. The amount of GTP-bound RhoA was strongly increased in DLC1-deficient MDA-MB-468 cells, whereas total RhoA levels were similar (Figure 3a) . To generate a quantitative result, we performed a Rho G-LISA assay demonstrating a significant increase of active, GTPbound RhoA in MDA-MB-468 cells as compared with MCF7 cells (Figure 3a , right).
In agreement with these observations, the DLC1-deficient HCC cell line HuH7 also showed higher RhoA-GTP levels than the hepatoma cell line HepG2 (Figure 3b ). RhoA activation was readily detectable in HepG2 cells upon stimulation with lysophosphatidic acid, whereas there was no further RhoA activation in HuH7 cells. These data indicate that RhoA is constitutively activated in carcinoma cells with DLC1 loss.
In order to analyze whether MKL1 nuclear accumulation is due to RhoA activation upon DLC1 loss, we tested the effect of the Rho Kinase inhibitor Y27632 in MDA-MB-468 and HuH7 cells. This inhibitor partially blocks the effects of RhoA on actin polymerization (Maekawa et al., 1999) . We observed that treatment with Y27632 resulted in cytoplasmic localization of MKL1 in HuH7 and MDA-MB-468 cells suggesting that the RhoA pathway is required for MKL1 nuclear localization (Figure 3c and Supplementary Figure S3) .
To further delineate the importance of the RhoA/ actin signaling pathway for MKL1 nuclear accumulation, we analyzed the actin cytoskeleton of HepG2, HuH7, MCF7 and MDA-MB-468 cells. Immunofluorescence analysis using a fluorescent phalloidin conjugate revealed increased stress fiber formation in MKL1/2 mediate tumorigenesis upon DLC1 loss S Muehlich et al DLC1-deficient HuH7 and MDA-MB-468 cells. In contrast, barely any stress fibers were detected in HepG2 and MCF7 cells ( Figure 3d ). For quantitative assessment, F-and G-actin was separated by ultracentrifugation into 100 000 g supernatant and pellet fractions. The cytoskeletal drug jasplakinolide, which stabilizes F-actin, served as a control to ensure correct partitioning between the supernatant containing G-actin and the pellet fractions with F-actin. Treatment with jasplakinolide resulted in quantitative recovery of cellular actin in the pellet fraction ( Figure 3e ). Consistent with the immunofluorescence analysis, the DLC1-deficient cell lines HuH7 and MDA-MB-468 were characterized by an approximately 1.7-fold increase in mean cellular F-actin content compared with the other cell lines ( Figure 3f ). To investigate whether the cytoskeletal alterations in DLC1-deficient cancer cells account for the nuclear localization of MKL1, we treated these cells with the actin polymerization inhibitor latrunculin B and examined MKL1 localization by immunofluorescence. As a result, MKL1 was redistributed to the cytoplasm ( Figure 3c and Supplementary Figure S3 ). Taken together, these data indicate that potentiation of the RhoA/actin signaling pathway upon DLC1 loss affects MKL1 localization.
MKL1 phosphorylation status contributes to nuclear localization in DLC1-deficient cells
Our previous studies demonstrated that phosphorylation of MKL1 affects MKL1 nuclear export (Muehlich et al., 2008) . Besides changes in the actin cytoskeleton, impairment of MKL1 phosphorylation could also contribute to nuclear localization of MKL1 in DLC1-deficient cells. To investigate this issue, we used a (Porter et al., 2004) . It is thus likely that RhoA activation caused by DLC1 loss limits ERK activation, thereby reducing phosphorylation and nuclear export of MKL1.
Activation of MKL/SRF target genes in DLC1-deficient cells Previous studies have shown that DLC1 is a potent tumor suppressor and its loss promotes HCC (Xue et al., 2008) . We therefore hypothesized that MKL1 may mediate the effects on tumorigenesis by affecting tumor-relevant SRF target genes. Thus, we generated HuH7 cells transformed with a lentiviral shRNA vector targeting both MKL1 and MKL2, here referred to as MKL1/2 KD cells. This 'double-KD' strategy was used because our previous results in fibroblasts demonstrated that a single KD of MKL1 is not sufficient to suppress immediate early gene expression (Cen et al., 2003) . There is only one shRNA sequence targeting MKL1 and MKL2, which could be used to generate stable MKL1/2 KD cells (Medjkane et al., 2009; Lee et al., 2010) . Control cells contained a lentiviral vector with an shRNA sequence that does not target known genes. MKL1 expression was downregulated by 85% at protein and RNA levels ( Figure 5a ). Two immediate early genes known to be SRF target genes (Selvaraj and Prywes, 2004; Miano et al., 2007; Muehlich et al., 2007) , namely connective tissue growth factor (CTGF) and integrin alpha 5 (Itga5), showed preferential expression in HuH7 versus HepG2 cells, as well as MDA-MB-468 versus MCF7 cells (Figure 5b and Supplementary Figure S4) . Both have been reported to have an important role in tumorigenesis (Friedl and Wolf, 2003; Mazzocca et al., 2010) . However, MKL dependence has not been determined yet. We found that MKL1/2 shRNAs resulted in a marked reduction in CTGF and Itga5 expression, indicating that both genes are MKL-dependent ( Figure 5b ). Next, we performed quantitative RT-PCR for HuH7 and HepG2 cells treated with and without serum. We reasoned that if MKL1/2 is constitutively nuclear in HuH7 cells, it Figure S4) . The same expression pattern was observed for Cyr61, a known MKL/SRF-dependent immediate early gene that promotes tumor growth (Supplementary Figure S5) To confirm that enhanced CTGF and Itga5 expression was caused by loss of DLC1 expression, we reconstituted DLC1 expression by transient transfection with Flag-DLC1-coding vectors. DLC1 strongly suppressed CTGF and Itga5 expression (Figure 5d ). We conclude that DLC1 loss leads to constitutive activation of the MKL-dependent, tumor-relevant target genes CTGF, Itga5 and Cyr61.
MKL1/2 is required for cell motility upon DLC1 loss Itga5 has a key role in tumor-cell motility and metastasis (Friedl and Wolf, 2003) . This fact and the role of RhoA in regulating actin stress fibers led us to investigate whether MKL1/2 and DLC1 affect cell migration. Therefore, we performed scratch assays in hepatocyte monolayers expressing DLC1 shRNA and/or MKL1/2 shRNA. A DLC1 KD efficiency of about 90% was achieved, as determined by RT-PCR. MKL1 expression was downregulated by 85% at the protein level (Figure 6a) .
The wound-healing assays revealed a strong increase in cell motility in the absence of DLC1 (Figure 6b ). MKL1/2 shRNA was able to revert this effect, suggesting that MKL1 exerts the effect on cell motility caused by DLC1 loss. To corroborate the anti-migratory effect of MKL1 in tumor cells with DLC1 loss, we used the established HuH7 MKL1/2 KD cell line for the scratch assays. While wound closure was observed in HuH7 control cells within 18 h, it was significantly delayed in HuH7 MKL1/2 KD cells (Figure 6c) .
We also stably introduced the lentiviral MKL1/2 shRNA into the DLC1-deficient mammary carcinoma cell line MDA-MB-468 to exclude a liver cell-specific effect. We also observed a significant reduction in cell motility of about 4-fold (Figure 6d ). Moreover, upon MKL1/2 depletion, phalloidin staining revealed a significant decrease in the number of protrusive structures, named filopodia, as well as a reduction in actin stress fibers that cross the cell (Figure 6e ). These data provide compelling evidence that MKL1/2 is required for cell motility upon DLC1 loss. MKL1/2 mediate tumorigenesis upon DLC1 loss S Muehlich et al MKL1/2 is required for cell growth upon DLC1 loss Besides enhanced cell migration, another DLC1-dependent hallmark of HCC cells is anchorage-independent cell growth (Wong et al., 2005) . To further substantiate that MKL1/2 confer cancer cell-specific features caused by DLC1 loss, we compared anchorage-independent growth of HuH7 control cells and HuH7 MKL1/2 KD cells in soft agar culture. Intriguingly, MKL1/2 KD cells did not grow on soft agar at all (Figure 7a ). This finding suggests that MKL1/2 depletion is sufficient to abolish anchorage-independent cell growth in HuH7 cells. Next, we asked whether MKL1/2 is required for cell proliferation in HCC cells that lack DLC1. We observed that HuH7 MKL1/2 KD cells exhibited a growth rate of about 50% compared with HuH7 cells (Figure 7b ). The effect of MKL1/2 KD on HuH7 cell proliferation resembled that of DLC1 reconstitution (Figure 7b) . The notion that depletion of MKL1 is able to revert enhanced cell proliferation caused by DLC1 loss was further supported by a 50% reduction of cell proliferation in MDA-MB-468 MKL1/2 KD cells (Figure 7c) .
Collectively, the findings presented here reveal that MKL1/2 is required for anchorage-independent cell growth and enhanced cell proliferation.
Discussion
Nuclear localization of MKL1/2 is a prerequisite for its function as a transcriptional activator. In fibroblasts, inactive MKL1 shuttles continuously between cytoplasm and nucleus; nuclear accumulation of MKL1 occurs only upon stimulation with serum due to an inhibition of nuclear export (Miralles et al., 2003; Vartiainen et al., 2007) . In this report, we provide evidence that MKL1/2 exhibits nuclear localization in various hepatocellular and mammary carcinoma cell lines and human HCC tissue samples that lack the tumor suppressor DLC1. We propose a model in which DLC1 loss activates RhoA, which controls F-actin formation leading to nuclear accumulation of MKL1/2 and activation of tumor-relevant SRF target genes (Figure 7d ). Besides activation of RhoA/actin signaling, impairment of MKL1 phosphorylation in tumor cells lacking DLC1 contributes to nuclear localization of MKL1. Previous studies by others and us have suggested that nuclear export is facilitated by ERK 1/ 2-mediated MKL1 phosphorylation and increased actin binding (Vartiainen et al., 2007; Muehlich et al., 2008) . Impairment of MKL1 phosphorylation in MKL1/2 mediate tumorigenesis upon DLC1 loss S Muehlich et al DLC1-deficient cancer cells is due to a failure of ERK activation caused by constitutively active RhoA, because ERK activation as well as MKL1 phosphorylation were reconstituted when RhoA was inhibited. Nuclear localization of MKL1 is required, but not sufficient for activation of target genes. For maximal transcriptional activity, MKL1 has to dissociate from actin (Vartiainen et al., 2007) . In addition, a group of SRF-transcriptional co-regulators named ternary complex factors has been shown to function as repressors of some MKL1/2 target genes (Lee et al., 2010) . We therefore sought to determine whether the nuclear localization of MKL1/2 in DLC1-deficient hepatocellular and mammary carcinoma cells results in activation of its target genes. We first tested the expression of CTGF, which has been classified as an SRF-dependent target gene (Muehlich et al., 2007; Medjkane et al., 2009) . CTGF also appeared in a recent microarray study by Medjkane et al. as a MKL-dependent target gene (Medjkane et al., 2009) . Indeed, CTGF expression was constitutively activated in DLC1-deficient HuH7 cells, whereas HepG2 hepatoma cells displayed low basal levels of CTGF expression and strong serum inducibility. Activation of CTGF expression was due to DLC1 loss, because rescue of DLC1 suppressed CTGF expression. Hepatocellular and breast cancers contain high levels of CTGF, which has been shown to have a role in tumor progression (Xie et al., 2001; Mazzocca et al., 2010) .
These data provided the basis for our hypothesis that MKL1/2 might mediate the effects of DLC1 loss on tumorigenesis via MKL1/2 target genes. Consistent with this, the known MKL/SRF-dependent immediate early gene Cyr61, which promotes tumor growth was strongly induced in DLC1-deficient HuH7 cells. We identified a novel target gene, Itga5, that exhibited a DLC1-and MKL-dependent regulation. Itga5 has a key role in cell motility and metastasis (Friedl and Wolf, 2003) . Alterations in the expression profile of Itga5 have been shown to have dramatic consequences for cell-matrix adhesion dynamics and cell motility (Truong and Danen, 2009 ). We analyzed whether MKL1/2 might therefore be responsible for the enhanced cell motility that was observed in response to DLC1 loss (Goodison et al., 2005; Heering et al., 2009 ). To test this hypothesis, we MKL1/2 mediate tumorigenesis upon DLC1 loss S Muehlich et al generated DLC1/MKL1/2 KD hepatocytes and subjected them to wound-healing assays. We observed a strong enhancement of cell motility in DLC1 KD hepatocytes. Consistent with this result, Wong et al. also found increased cell motility in DLC1-deficient HCC cells. They went on to show that this increase was due to DLC1 loss, because reconstitution with DLC1 significantly inhibited cell motility of HCC cells (Wong et al., 2005) . We found that MKL1/2 depletion abrogated the increase in cell motility upon DLC1 KD, indicating that MKL1/2 is required for cell motility upon DLC1 loss. A similar reduction in cell motility was achieved upon MKL1/2 KD in the DLC1-deficient mammary carcinoma cell line MDA-MB-468 and HCC cell line HuH7. Depletion of MKL1/2 in these cells resulted in a significant reduction in filopodia. These protrusive structures of a motile cell are considered a characteristic of invasive cancer cells (Mattila and Lappalainen, 2008) . The phenotype of MKL1/2 KD HuH7 cells resembles SRFÀ/À phenotypes that display an almost complete lack of filopodia (Knoll et al., 2006; Knoll, 2010) . These results strongly argue that DLC1 exerts its effects on cell migration through MKL1 and SRF.
One of the most intriguing pathogenetic insights gleaned from our study is that anchorage-independent cell growth is completely abrogated in MKL1/2 KD HCC cells. The capability of anchorage-independent cell growth is a hallmark of DLC1-deficient HCC cells (Wong et al., 2005) . This finding provides compelling evidence that depletion of MKL1/2 is able to suppress cancer cell growth caused by DLC1 loss.
DLC1-deficient HCC cells are also characterized by enhanced cell proliferation. This pathology of tumors appears to be derived from DLC1 KD as seen by the high proliferative index measured by Ki-67 immunohistochemistry (Xue et al., 2008) . We found that depletion of MKL1/2 in HCC cells inhibits cell proliferation, thereby resembling the effect of DLC1 reintroduction into these cells (Wong et al., 2005) . Further support for a function of MKL1/2 as mediators of cancer cell growth upon DLC1 loss comes from the notion that nuclear staining of MKL1 in HCCs correlated with Ki-67 expression. Medjkane et al. reported that depletion of MKL1/2 did not affect cell proliferation of MDA-MB-231 and B16F2 cells. This discrepancy may be attributable to the presence of DLC1 in MDA-MB-231 and B16F2 cells. Consistent with our results, they showed that MKL1/2 are required for motility and experimental metastasis in these two cell lines (Medjkane et al., 2009) .
Our study provides novel insight into the mechanism by which loss of DLC1 initiates tumorigenesis. As MKL1/2 has a key role in this process, this pathway may provide promising pharmacological targets for cancer therapy.
Materials and methods
Cell culture, transfections and reagents HuH7, MDA-MB-468, MCF7 cells and DLC1 KD hepatocytes were grown in DMEM medium. HepG2 and HCC1143 cells were cultivated in RPMI medium, Hep3B cells in MEM medium and MDA-MB-453 cells in Leibovitz medium. For MCF10F, DMEM:F12 (1:1) medium containing 5% horse serum, 20 ng/ml EGF, 0.01 mg/ml insulin and 500 mg/ml hydrocortison was used.
HuH7 and MDA-MB-468 cells stably expressing MKL1/2 shRNA or control shRNA (non-target shRNA control vector, SHC002, Sigma, Taufkirchen, Germany) were generated by lentiviral infection followed by puromycin (1 mg/ml) selection. A sequence (5 0 -CATGGAGCTGGTGGAGAAGAA-3 0 ) targeting both MKL1 and MKL2 was used for shRNA expression as described (Lee et al., 2010) .
For transient transfections, Lipofectamine 2000 reagent (Invitrogen, Karlsruhe, Germany) was used. RhoA activity was measured with RhoA Activation Assay Kits according to the manufacturer's instructions (Cytoskeleton, Denver, CO, USA and NewEast Biosciences, King of Prussia, PA, USA).
Actin fractionation
Cells were lysed in actin lysis buffer (50 mM NaCl, 1 mM EDTA, 0.5% Triton X-100, 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid). After ultracentrifugation of the lysate for 1 h at 100 000 g, the supernatant was separated from the pellet. The pellet was resuspended in actin lysis buffer and sonicated. 5 ml of each fraction was subjected to immunoblotting using anti-actin antibody (Sigma).
Immunofluorescence Cells were fixed with 4% paraformaldehyde in phosphatesaline buffer for 10 min. Latrunculin B (1 mM, Calbiochem, Darmstadt, Germany) and Y27632 (5 mM, Biozol) were added to the cells 45 min before fixation. Cells were then permeabilized with 0.2% Triton X-100 in phosphate-saline buffer for 7 min and blocked with 1% bovine serum albumin in phosphate-saline buffer for 30 min at 37 1C. Incubations with goat anti-MRTF-A (C-19) antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-MKL2 antibody (Hanna et al., 2009 ) and mouse anti-FLAG M2 antibody (Sigma) were carried out for 1 h. The secondary antibodies, labeled with the Alexa Fluor 488/555 dye (Invitrogen), were added to the cells for 30 min. Cells were washed four times in phosphate-saline buffer after antibody incubations and before mounting. Actin filaments were stained with phalloidin coupled to Alexa Fluor 488 (Invitrogen). Images were obtained using a confocal microscope (Zeiss, Oberkochen, Germany).
Immunoblotting
Cells were lysed in 100 ml radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.5% Sodium deoxycholate, 2 mM EDTA, 1% Nonidet P-40, 0.1% SDS) containing a protease inhibitor mixture (Calbiochem). The lysates were kept on ice for 15 min and were then cleared by centrifugation at 13 000 g for 10 min at 4 1C. The supernatant was boiled with Laemmli sample buffer, and the proteins subsequently resolved on SDS-polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were then transferred to polyvinylidene fluoride (PVDF) membranes and immunoblotted with the respective antibody. The primary antibodies used were goat anti-MRTF-A (C-19), goat anti-CTGF (L-20) (Santa Cruz) and mouse anti-DLC1 (BD Biosciences, Heidelberg, Germany). The phospho-specific MKL antibody and the MKL2 antibody were described previously (Cen et al., 2003; Muehlich et al., 2008) . Rat antitubulin (Millipore, Schwalbach, Germany), mouse monoclonal anti-hsp90 (Santa Cruz) and rabbit anti-GAPDH (Sigma) were used for loading controls. Blots were detected at a luminescent imager (Peqlab, Erlangen, Germany).
RNA extraction, cDNA synthesis and quantitative real time PCR analysis Total RNA was extracted from hepatocellular and mammary carcinoma cell lines using TRIzol reagent according to the manufacturer's directions (Invitrogen). RNA (1 mg) was primed with random hexamers and reverse-transcribed into cDNA with SuperScript II Reverse Transcriptase (Invitrogen). Amounts of cDNA corresponding to 100 ng of RNA were used in SYBR Green based real-time PCR. PCR reactions were carried out using the LightCycler 480 Real-Time PCR System (Roche, Mannheim, Germany). Specificity of amplified products was monitored by performing melting curves at the end of each amplification. The relative mRNA level was calculated using the determination of cDNA levels of 18S rRNA as a control.
Tissues and immunohistochemistry
Formalin-fixed and paraffin-embedded tissue specimens were provided by the tissue bank of the National Center for Tumor Diseases (ethics proposal 206/2005, University of Heidelberg). The tissue micro-array contained two representative areas of 120 HCCs and 20 normal livers without significant pathological alterations. MKL1 and DLC1 expression was assessed by a scoring system, as previously described (Singer et al., 2007) . An IHC score of >2 was considered as positive for nuclear MKL1 staining. The evaluation was done independently by two experienced investigators (SS and KB). Immunohistochemistry was performed, as previously described, with citrate buffer pretreatment at pH 6 (Prange et al., 2003) . The primary antibodies were as follows: rabbit anti-human MKL1, rabbit anti-human DLC1 (Atlas Antibodies, Stockholm, Sweden) and rabbit anti-human Ki-67 (DAKO, Hamburg, Germany). The Spearman rank coefficient served as a statistical measure of association. The non-parametric Mann-Whitney U-test was used for statistical comparison.
Soft agar assay
The feeder layer consisted of 0.6% agar (Difco, Lawrence, KS, USA). 4 Â 10 4 cells were mixed to form a top layer of 0.3% agar. Following 2 weeks of incubation , images were taken after staining with 1 mg/ml Iodonitrotetrazoliumchlorid (Serva, Heidelberg, Germany) in Hank's BSS (Sigma).
Cell proliferation assay
Cells were harvested at 24-hour intervals for 7 days and cell numbers were counted with hematocytometer.
Scratch-wound assay
Cells were allowed to grow to a confluent monolayer before scratching a wound using a pipette tip. The mobilization of cells behind the wound edge was monitored using a Zeiss microscope and the AxioVision software.
